Gilead Signs an Exclusive Worldwide License Agreement with Novartis for its Three Preclinical Antiviral Programs

Shots:

• Novartis to receive up front and up to $291M upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. Gilead acquires exclusive WW rights to develop and commercialize novel small molecules against three undisclosed targets
• The focus of the agreement is to develop therapies for treat human rhinovirus, influenza and herpes viruses with limited therapeutic options, further improving QoL  
• Biktarvy (qd) is an INSTI-based triple-therapy STR combining bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg (BIC/FTC/TAF) approved for HIV-1 Infection in Japan. Additionally, Gilead has an antiviral portfolio which includes therapies for HIV, hepatitis B and hepatitis C, as well as influenza infection

Click here to read full press release/ article | Ref: Gilead | Image: Leo Associates